Navigation Links
Edison Pharmaceuticals Receives Commendation From the City of San Jose
Date:7/6/2008

Mayor Chuck Reed recognizes contribution to city and children with rare

diseases

SAN JOSE, Calif., July 7 /PRNewswire/ -- Edison Pharmaceuticals, Inc., a privately held biotechnology company located in San Jose, CA, announced today the receipt of a commendation from the City of San Jose, acknowledging the company's contributions in fighting rare childhood diseases. The commendation recognizes "Edison for outstanding achievements in developing drugs for unmet medical need, and its commitment to public-private partnership, and extend our best wishes for many years of success in positively impacting the lives of children and individuals with mitochondrial diseases in America and throughout the world."

Mayor Chuck Reed and Councilmember Forrest Williams presented the commendation to Edison Chairman and CEO, Dr. Guy Miller on February 12th, 2008 at City Hall. "Since starting operations at the San Jose BioCenter in January 2006, Edison Pharmaceuticals has helped to make San Jose a center of life science technology. Edison is doing a remarkable job by focusing its R&D efforts on discovering a treatment for mitochondrial diseases -- that impair energy metabolism, and for which there exist no drugs," said Mayor Chuck Reed. "I congratulate Edison on achieving high performance standards and for the commitment of its founder Dr. Guy Miller and his team to improving the lives of children throughout the world."

About Edison Pharmaceuticals

Edison Pharmaceuticals, Inc., a biotechnology company based in Silicon Valley California at the San Jose Biocenter, is focused on developing drugs for rare diseases that impair energy metabolism. Edison possesses a technology platform and specialized knowledge in redox therapeutics -- pivotal to targeting genetic defects in the mitochondria. The Company's initial focus is on inherited diseases of the mitochondrial respiratory chain. The company is leveraging insights derived from those studies to pursue other diseases that share common mechanisms, such as Huntington's disease and diseases of aging. Edison has obtained substantial peer-reviewed grants from multiple foundations and the National Institutes of Health.


'/>"/>
SOURCE Edison Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Edison Innovation Fund Helps Tris Pharma Expand
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , ... October 11, 2017 , ... ... gene in its endogenous context, enabling overexpression experiments and avoiding the use of ... small RNA guides is transformative for performing systematic gain-of-function studies. , This ...
(Date:10/11/2017)... Netherlands and LAGUNA HILLS, Calif. ... Institute of Cancer Research, London (ICR) ... MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with ... known as MUK nine . The University of ... which is partly funded by Myeloma UK, and ICR will ...
(Date:10/10/2017)... (PRWEB) , ... October 10, ... ... development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed ... targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... optimization firm for the life sciences and healthcare industries, announces a presentation by ... Francisco. , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present ...
Breaking Biology Technology:
(Date:5/16/2017)... May 16, 2017  Veratad Technologies, LLC ( www.veratad.com ... age and identity verification solutions, announced today they will ... 2017, May 15 thru May 17, 2017, in ... International Trade Center. Identity impacts the ... in today,s quickly evolving digital world, defining identity is ...
(Date:4/19/2017)... ALBANY, New York , April 19, 2017 /PRNewswire/ ... highly competitive, as its vendor landscape is marked by ... in the market is however held by five major ... and Safran. Together these companies accounted for nearly 61% ... majority of the leading companies in the global military ...
(Date:4/13/2017)... India , April 13, 2017 According to ... Proofing, Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, ... MarketsandMarkets™, the IAM Market is expected to grow from USD 14.30 Billion ... Growth Rate (CAGR) of 17.3%. ... MarketsandMarkets ...
Breaking Biology News(10 mins):